Right. So, ImmunityBio (IBRX +41.36%). Closed at $8.54 yesterday. A 41% jump. Honestly, it felt…predictable. The EU gave Anktiva conditional marketing authorization for bladder cancer. Which, let’s be real, is a big deal. They moved 78.5 million shares. That’s…a lot of hope being priced in. They IPO’d in 2015, and have been circling the drain ever since, down 75%. It’s the kind of stock that makes you question all your life choices. I’ve been watching them for a while now, and frankly, it’s been a rollercoaster. A really, really messy rollercoaster.
How the Markets Played Along
The S&P 500 did its usual thing, inching up 0.53% to 6,880. The Nasdaq Composite, ever the optimist, added 0.78%, landing at 22,754. Biotech was…mixed. Iovance Biotherapeutics managed a small gain (+3.82%), while Krystal Biotech decided to take a nap (-1.58%). Honestly, the biotech sector feels like a group therapy session. Everyone’s trying to appear stable, but underneath it all…chaos.
What This Actually Means (For Those Paying Attention)
Okay, so Anktiva. Conditional marketing authorization in Europe. It’s used with BCG, for bladder cancer patients who’ve stopped responding to the usual treatment. Which, let’s be clear, is a big deal for those patients. But for us? It opens up access to over 30 new countries. That’s potential revenue, people. And potential for…well, let’s just say I’ve been quietly accumulating shares. Don’t tell anyone. It’s a bit of a gamble, admittedly. But I like a gamble. Especially when it involves potentially disruptive immunotherapy.
They’re projecting some…ambitious growth. Quadrupling the stock in 2026. 700% sales increase in 2025. Approvals from Saudi Arabia. Promising data on lung cancer. Solid tumor applications. It all sounds fantastic. And I’m not saying it won’t happen. I’m just saying…read the fine print. And maybe, just maybe, have an exit strategy. Because if it doesn’t happen? Well, let’s just say I’ll be having a very awkward conversation with my broker.
Look, Anktiva is promising. Genuinely. But ImmunityBio is still…fragile. Highly dependent on good news. One negative trial, one regulatory hiccup, and this whole thing could come crashing down. So, yes, it’s a volatile stock. But that’s precisely why I’m interested. Because sometimes, the biggest rewards come with the biggest risks. Just…don’t blame me if it all goes south.
Read More
- Top 20 Dinosaur Movies, Ranked
- 20 Movies Where the Black Villain Was Secretly the Most Popular Character
- Celebs Who Narrowly Escaped The 9/11 Attacks
- 25 “Woke” Films That Used Black Trauma to Humanize White Leads
- The 10 Most Underrated Jim Carrey Movies, Ranked (From Least to Most Underrated)
- Transformers Under the Microscope: What Graph Neural Networks Reveal
- The Best Directors of 2025
- Every Notable ‘Star Trek: The Original Series’ Actor Who Died
- 22 Films Where the White Protagonist Is Canonically the Sidekick to a Black Lead
- Trading on Thin Air: AI Agents Conquer Crypto Volatility
2026-02-19 01:23